Phase 2 HNSCC Trial: Pertuzumab, Lenvatinib, Apr 2026
Summary
A single-arm, single-center Phase 2 clinical trial (NCT07550972) has been registered to evaluate the efficacy of neoadjuvant treatment with Pertuzumab combined with Lenvatinib for patients with locally advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC). The trial is designated as Phase 2 with an April 2026 date. This registration provides public visibility into an active oncology research program studying a novel drug combination targeting HNSCC, a cancer with significant unmet medical need.
“Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new clinical trial registration has been published on ClinicalTrials.gov for a Phase 2 study evaluating the combination of Pertuzumab and Lenvatinib as neoadjuvant treatment for locally advanced HNSCC. The trial is registered as NCT07550972 and is described as a single-arm, single-center study assessing efficacy.
For clinical investigators and oncology research programs, this registration signals active recruitment or planning for a targeted therapy approach combining these two agents for head and neck cancer. Pharmaceutical companies with interests in these drug compounds or in HNSCC treatment development should be aware of this competing or complementary research program in the landscape.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.
Phase 2 NCT07550972 Kind: PHASE2 Apr 24, 2026
Abstract
A single-arm, single-center clinical trial evaluating efficacy (Phase #)
Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: A single-arm, single-center clinical trial evaluating efficacy
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.